198 related articles for article (PubMed ID: 19081789)
41. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
42. Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120.
Akerblom L; Hinkula J; Broliden PA; Mäkitalo B; Fridberger T; Rosen J; Villacres-Eriksson M; Morein B; Wahren B
AIDS; 1990 Oct; 4(10):953-60. PubMed ID: 1702001
[TBL] [Abstract][Full Text] [Related]
43. Induction of neutralizing antibodies against human immunodeficiency virus type 1 using synthetic peptide constructs containing an immunodominant T-helper cell determinant from vpr.
Sarobe P; Lasarte JJ; Golvano JJ; Prieto I; Gullón A; Soto MJ; Labarga P; Prieto J; Borrás-Cuesta F
J Acquir Immune Defic Syndr (1988); 1994 Jul; 7(7):635-40. PubMed ID: 8207641
[TBL] [Abstract][Full Text] [Related]
44. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.
Verrier F; Burda S; Belshe R; Duliege AM; Excler JL; Klein M; Zolla-Pazner S
J Virol; 2000 Nov; 74(21):10025-33. PubMed ID: 11024131
[TBL] [Abstract][Full Text] [Related]
45. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains.
Kayman SC; Wu Z; Revesz K; Chen H; Kopelman R; Pinter A
J Virol; 1994 Jan; 68(1):400-10. PubMed ID: 7504740
[TBL] [Abstract][Full Text] [Related]
46. Conformational Engineering of HIV-1 Env Based on Mutational Tolerance in the CD4 and PG16 Bound States.
Heredia JD; Park J; Choi H; Gill KS; Procko E
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894475
[TBL] [Abstract][Full Text] [Related]
47. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
[TBL] [Abstract][Full Text] [Related]
48. An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates.
Wise MC; Hutnick NA; Pollara J; Myles DJ; Williams C; Yan J; LaBranche CC; Khan AS; Sardesai NY; Montefiori D; Barnett SW; Zolla-Pazner S; Ferrari G; Weiner DB
J Virol; 2015 Sep; 89(18):9154-66. PubMed ID: 26085155
[TBL] [Abstract][Full Text] [Related]
49. Identification of a novel broadly HIV-1-neutralizing antibody from a CRF01_AE-infected Chinese donor.
Ju B; Li D; Ren L; Hou J; Hao Y; Liang H; Wang S; Zhu J; Wei M; Shao Y
Emerg Microbes Infect; 2018 Nov; 7(1):174. PubMed ID: 30382080
[TBL] [Abstract][Full Text] [Related]
50. Identification of Non-HIV Immunogens That Bind to Germline b12 Predecessors and Prime for Elicitation of Cross-clade Neutralizing HIV-1 Antibodies.
Yang Z; Li J; Liu Q; Yuan T; Zhang Y; Chen LQ; Lou Q; Sun Z; Ying H; Xu J; Dimitrov DS; Zhang MY
PLoS One; 2015; 10(5):e0126428. PubMed ID: 26010511
[TBL] [Abstract][Full Text] [Related]
51. Rationally designed carbohydrate-occluded epitopes elicit HIV-1 Env-specific antibodies.
Zhu C; Dukhovlinova E; Council O; Ping L; Faison EM; Prabhu SS; Potter EL; Upton SL; Yin G; Fay JM; Kincer LP; Spielvogel E; Campbell SL; Benhabbour SR; Ke H; Swanstrom R; Dokholyan NV
Nat Commun; 2019 Feb; 10(1):948. PubMed ID: 30814513
[TBL] [Abstract][Full Text] [Related]
52. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
Gorny MK; Williams C; Volsky B; Revesz K; Cohen S; Polonis VR; Honnen WJ; Kayman SC; Krachmarov C; Pinter A; Zolla-Pazner S
J Virol; 2002 Sep; 76(18):9035-45. PubMed ID: 12186887
[TBL] [Abstract][Full Text] [Related]
53. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.
Beddows S; Franti M; Dey AK; Kirschner M; Iyer SP; Fisch DC; Ketas T; Yuste E; Desrosiers RC; Klasse PJ; Maddon PJ; Olson WC; Moore JP
Virology; 2007 Apr; 360(2):329-40. PubMed ID: 17126869
[TBL] [Abstract][Full Text] [Related]
54. Sequential antigen panning for selection of broadly cross-reactive HIV-1-neutralizing human monoclonal antibodies.
Zhang MY; Dimitrov DS
Methods Mol Biol; 2009; 562():143-54. PubMed ID: 19554293
[TBL] [Abstract][Full Text] [Related]
55. Selection of peptide mimics of HIV-1 epitope recognized by neutralizing antibody VRC01.
Chikaev AN; Bakulina AY; Burdick RC; Karpenko LI; Pathak VK; Ilyichev AA
PLoS One; 2015; 10(3):e0120847. PubMed ID: 25785734
[TBL] [Abstract][Full Text] [Related]
56. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.
Dhillon AK; Donners H; Pantophlet R; Johnson WE; Decker JM; Shaw GM; Lee FH; Richman DD; Doms RW; Vanham G; Burton DR
J Virol; 2007 Jun; 81(12):6548-62. PubMed ID: 17409160
[TBL] [Abstract][Full Text] [Related]
57. Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost.
Joachim A; Ahmed MIM; Pollakis G; Rogers L; Hoffmann VS; Munseri P; Aboud S; Lyamuya EF; Bakari M; Robb ML; Wahren B; Sandstrom E; Nilsson C; Biberfeld G; Geldmacher C; Held K
Front Immunol; 2020; 11():719. PubMed ID: 32411138
[TBL] [Abstract][Full Text] [Related]
58. Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.
Wagner R; Modrow S; Böltz T; Fliessbach H; Niedrig M; von Brunn A; Wolf H
Arch Virol; 1992; 127(1-4):139-52. PubMed ID: 1456889
[TBL] [Abstract][Full Text] [Related]
59. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
[TBL] [Abstract][Full Text] [Related]
60. Passive immunization as tool to identify protective HIV-1 Env epitopes.
Kramer VG; Siddappa NB; Ruprecht RM
Curr HIV Res; 2007 Nov; 5(6):642-55. PubMed ID: 18045119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
